Journal
EXPERT REVIEW OF NEUROTHERAPEUTICS
Volume 14, Issue 1, Pages 29-38Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1586/14737175.2014.853617
Keywords
anxiolytic; drug therapy; generalized anxiety disorder; pregabalin; randomized controlled trials
Categories
Funding
- Novartis
- AstraZeneca
- Servier
- Pfizer
- Bristol Myers-Squibb
- Boehringer
- Mundipharma
- Actavis
- Schwarz Pharma
- Shire
Ask authors/readers for more resources
Generalized anxiety disorder (GAD) is one of the most common psychiatric disorders and clinically characterized by both psychological anxiety and somatic symptoms (muscular tension and autonomic symptoms). Next to serotonergic antidepressants, the Ca2+ channel alpha(2)delta ligand pregabalin is an approved first-line treatment of GAD in many countries. Pregabalin is considered effective against psychological and somatic anxiety symptoms alike. However, occurrence of discontinuation syndromes and a growing number of reports regarding abuse or dependence during the last years are concerns, particularly in patients with a history of addictive behavior. Here we review key issues of GAD and the pharmacology and pharmacokinetics of pregabalin. Above all, we evaluate evidence from available randomized placebo-controlled as well as head-to-head clinical trials with other drugs regarding its efficacy and safety in the GAD treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available